MedTrace Logo

Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

NCT00252291 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2009-12-01

No results posted yet for this study

Summary

This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 \>70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.

Conditions

Interventions

DRUG

Aridol

DRUG

Methacholine

PROCEDURE

Exercise challenge

Sponsors & Collaborators

  • Syntara

    lead INDUSTRY

Principal Investigators

  • David Pearlman, MD · Colorado Asthma and Allergy Centers, Denver, CO

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252291 on ClinicalTrials.gov